Multiple sclerosis (MS) is an inflammatory CNS disease characterized by multifocal areas of demyelination; usually it arises in young adults, but can also occur in children (under the age of 10) and adolescents (under the age of 18). As in adult, pediatric MS (PMS) diagnosis is based on the demonstration of multiple demyelination episodes separated in time and spaces. Diagnostic criteria realized for childhood are similar to those employed for adults. Although clinical and imaging features of PMS can be similar to those of adults, the disease is often characterized by a more aggressive course and atypical imaging findings, with giant and pseudotumoral plaques. Differential diagnosis between PMS and ADEM could be difficult: clinical findings and MRI are necessary; sometimes MRI follow-up is required for definitive diagnosis.
ShawCMAlwordEcJr. MS beginning in infancy. J Child Neurol. 1987; 2: 252–256.
6.
NessJMChabasDSadovnickAD. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007;68 (Suppl 2): S37–S45.
7.
MikaeloffYAdamsbaumCHussonB. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004; 127: 1942–1947.
8.
ZelnikNGaleADShelburneSAJr. Multiple sclerosis in black children. J Child Neurol. 1991; 6: 53–57.
9.
MicheliCBozzaoA. Multiple sclerosis in the pediatric age and Schilder disease (abs). Neuroradiology. 1996: S56.
10.
SimoneILCarraraDTortorellaC. Course and prognosis in early-onset MS: comparison with adultonset forms. Neurology. 2002; 59: 1922–1928.
11.
MillerDHBarkhofFMontalbanX. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurol. 2005; 4: 281–288.
12.
Optic neuritis study group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology. 1997; 49: 1404–1413.
13.
McDonaldWICompstonAEdanG. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001; 50: 121–127.
PolmanCHReingoldSCEdanG. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58: 840–846.
16.
BarkhofFFilippiMMillerDH. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120: 2059–2069.
17.
TintoreMRoviraAMartinezMJ. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol. 2000; 21: 702–706.
18.
HahnCDShroffMMBlaserSI. MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort. Neurology. 2004; 62: 806–808.
19.
McAdamLCBlaserSIBanwellBL. Pediatric tumefactive demyelination: case series and review of the literature. Pediatr Neurol. 2002; 26: 18–25.
20.
ChaSPierceS. Dynamic contrast-enhanced T2*-w MRI of Tumefactive Demyelinating Lesions. Am J Neuroradiol. 2001; 22: 1109–1116.
21.
MalhotraHSJainKK. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler. 2009;15 (2): 193–203.
22.
FilippiMBozzaliMRovarisM. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003; 126: 433–437.
23.
BruhnHFrahmJMerboldtKD. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol. 1992; 32: 140–150.
24.
MezzapesaDMRoccaMAFaliniA. A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis. Arch Neurol. 2004; 61: 366–368.
25.
EiselePSzaboK. Reduced diffusion in a subset of Acute MS lesions: a serial multiparametric MRI study. Am J Neuroradiol. 2012; 33: 1369–73.
